Friday, 6 November 2026European Markets

ADOCIA Stock Impressive Rise On Wednesday, Outperforms Market

Loading stream...

(vianews) - the market ended the session with adocia (adoc.pa) rising 15.1% to €8.23 on wednesday while cac 40 dropped 0.69% to €7,609.15.

adocia's last close was €7.15, 55.75% under its 52-week high of €16.16.

about adocia

adocia sa, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. its proprietary biochaperone technological platform provides molecular delivery of therapeutic proteins. the company's clinical product pipeline includes insulin formulations, such as biochaperone lispro u100 and u200, which are ultra-rapid formulations based on rapid insulin lispro; biochaperone combo, a combination of acting insulin glargine and rapid-acting insulin lispro; and biochaperone lispram, a combination of prandial insulin with pramlintide, as well as m1pram, a combination of insulin m1 and pramlintide. its preclinical pipeline includes products for the treatment of diabetes and obesity comprising adoshell islets, an implant containing islets of langerhans; adoral sema, an oral delivery of semaglutide; and adogel sema for the long-term delivery of therapeutic agents. the company has a strategic alliance with tonghua dongbao pharmaceutical co., ltd. to develop and commercialize biochaperone lispro and biochaperone combo in china and other asian and middle eastern territories. adocia sa was incorporated in 2005 and is headquartered in lyon, france.

earnings per share

as for profitability, adocia has a trailing twelve months eps of €-1.9.

yearly top and bottom value

adocia's stock is valued at €8.23 at 22:30 est, way below its 52-week high of €16.16 and way above its 52-week low of €2.74.

volume

today's last reported volume for adocia is 230320 which is 166.52% above its average volume of 86415.

volatility

adocia's last week, last month's, and last quarter's current intraday variation average was a positive 0.17%, a negative 1.25%, and a positive 2.86%.

adocia's highest amplitude of average volatility was 4.75% (last week), 3.11% (last month), and 2.86% (last quarter).

revenue growth

year-on-year quarterly revenue growth declined by 62.6%, now sitting on 10.84m for the twelve trailing months.

more news about adocia (adoc.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com